Aplagon is introducing APAC, a heparin proteoglycan mimetic aimed at treating thrombo-inflammatory diseases. The upcoming Phase 2a clinical trial will focus on peripheral arterial occlusive
Aplagon is introducing APAC, a heparin proteoglycan mimetic aimed at treating thrombo-inflammatory diseases. The upcoming Phase 2a clinical trial will focus on peripheral arterial occlusive